Across TCGA pan-cancer cohorts, RILPL1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RILPL1 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RILPL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RILPL1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where RILPL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	0.801	1.000	.030	7	view →
LSCC	OS	Tertile	All	0.738	0.886	.022	7	view →
HNSC	DFS	Quartile	IV	0.805	0.531	.021	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RILPL1 tumor-vs-normal RNA expression · all RILPL1 data types